We are live on ! Find out more

AIM

AIM ImmunoTech

AIM

Market cap $6.93M

0.2276 USD

-0.0061

2.61%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

0.2304

+0.0028

1.23%

1 day

-2.61%

5 days

-38.64%

1 month

-13.46%

3 months

-61.51%

6 months

-67.05%

Year to date

-80.87%

1 year

-90.67%

5 years

-99.89%

10 years

-100%

About: AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

Employees: 21

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 6.3%

Neutral 93.8%

Negative 0%

AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041

Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom

AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039

OCALA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office has granted a patent covering the use of the Company's drug Ampligen in combination with the PD-1 checkpoint inhibitor pembrolizumab for the treatment of cancer.

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039

AIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand Conference

Video webcast now available here

AIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand Conference

AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' Article

Article by CEO Thomas K. Equels calls for proactive evaluation of broad-spectrum antiviral countermeasures before novel viral threats emerge

AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' Article

AIM ImmunoTech Ahead of Schedule on ‘Last Dose' DURIPANC Critical Clinical Inflection Point

Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027 Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027

AIM ImmunoTech Ahead of Schedule on ‘Last Dose' DURIPANC Critical Clinical Inflection Point

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program

CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted the significant progress achieved across its pancreatic cancer development program and outlined a series of anticipated milestones that position the Company for what management believes could be a pivotal period in its evolution as a clinical-stage oncology company.

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

AIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New Experiences

LOS ANGELES--(BUSINESS WIRE)-- #aimsportsgroup--AIM Sports Group hosted the SoCal Cup ‘Showcase' tournament, one of the nation's leading tournament series for youth club volleyball, at the Los Angeles Convention Center (LACC) this past Father's Day weekend.The Showcase, operated by AIM Sports Group, drew more than 550 elite boys club volleyball teams of various age groups (12U through 18U) from across the nation and wowed visitors with a weekend experience of the highest level of competition, development, collegi.

AIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New Experiences

AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series

OCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will present in the Webull Corporate Connect Webinar Series being held virtually June 24-25, 2026.

AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

Study results expected to support design and initiation of a pivotal Phase 3 clinical trial in the treatment of metastatic pancreatic cancer Study results expected to support design and initiation of a pivotal Phase 3 clinical trial in the treatment of metastatic pancreatic cancer

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

See News Rankings

Price charts implemented using Lightweight Charts™